Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes

被引:9
|
作者
Tong, Yan [1 ]
Huang, Jian Qing [1 ]
Chen, Yang [1 ]
Tu, Mei [1 ]
Wang, Wei [1 ]
机构
[1] Fujian Med Univ, Longyan Affiliated Hosp 1, Longyan, Fujian, Peoples R China
关键词
liraglutide; sitagliptin; bowel preparation quality; gastrointestinal discomfort; gastrointestinal motility; DOSE POLYETHYLENE-GLYCOL; GLUCOSE; COLONOSCOPY; EXENATIDE; SUPERIOR; MOTILITY; TRANSIT;
D O I
10.3389/fphar.2023.1176206
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i) profoundly affect the gastrointestinal motor system, which may increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms. Hence, this observational study mainly aimed to assess the influence of GLP-1 RAs liraglutide and DPP-4i sitagliptin on bowel preparation in type 2 diabetes (T2DM). Method: This observational study consecutively enrolled T2DM scheduled for a colonoscopy. Participants were prospectively separated into the liraglutide group (n = 120), sitagliptin group (n = 120), and control group (n = 120) based on the current hypoglycemic regimen. 3L split-dose polyethylene glycol regimens were used for bowel preparation. Experienced gastrointestinal endoscopists conducted colonoscopies. Lawrance Bowel-Preparation Tolerability Questionnaire and Boston Bowel Preparation Scale (BBPS) were conducted to assess bowel cleaning quality, tolerability, and safety. Results: The incidence of inadequate bowel cleaning was 17.5% in the liraglutide group, 20.5% in the sitagliptin group, and 21.7% in the control group. The difference among the three groups was not statistically significant (p = 0.927). Meanwhile, there were no significant differences in the mean BBPS, cecal intubation time, and polyp-detecting rates among the three groups (all p > 0.0.05). Nausea, vomiting, and bloating scores were increased in the liraglutide group compared with the other two groups (p < 0.05), whereas most were mild or very mild. Subgroup analyses showed that the incidence of inadequate bowel cleaning in T2DM with diabetic peripheral neuropathy (DPN) was increased in the liraglutide group compared with the sitagliptin group (61.3% vs. 32.1%, p = 0.022) and control group (61.3% vs. 32.8%, p = 0.025). Conclusion: GLP-1RA liraglutide or DPP-4i sitagliptin did not significantly increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms during bowel preparation. Liraglutide may increase the incidence of inadequate bowel preparation in patients with DPN. This study reveal that more attention and aggressive bowel preparation regimens should be given to the T2DM with DPN.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Hormonal Responses during Hypoglycemia with Dipeptidyl Peptidase-4 Inhibitor Linagliptin and Glucagon-like Peptide-1 Receptor Agonist Liraglutide in Patients with Type 2 Diabetes
    Yabe, Daisuke
    Eto, Takashi
    Shiramoto, Masanari
    Irie, Shin
    Murotani, Kenta
    Seino, Yusuke
    Kuwata, Hitoshi
    Kurose, Takeshi
    Seino, Susumu
    Ahren, Bo
    Seino, Yutaka
    DIABETES, 2016, 65 : A304 - A304
  • [2] Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon- like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes
    Nauck, Michael A.
    Kahle, Melanie
    Baranov, Oleg
    Deacon, Carolyn F.
    Holst, Jens J.
    DIABETES OBESITY & METABOLISM, 2017, 19 (02): : 200 - 207
  • [3] The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review
    Chen, Chengcong
    Huang, Ying
    Dong, Guoqing
    Zeng, Yongmei
    Zhou, Ziqiong
    GYNECOLOGICAL ENDOCRINOLOGY, 2020, 36 (05) : 375 - 380
  • [4] Glucagon-like peptide-1 levels and dipeptidyl peptidase-4 activity in type 2 diabetes
    Senyigit, Abdulhalim
    Tabak, Omur
    Orbanoglu, Timur
    Karadag, Aytac
    Ugurlu, Serdal
    Uzun, Hafize
    Konukoglu, Dihlar
    CLINICAL AND INVESTIGATIVE MEDICINE, 2017, 40 (05): : E188 - E199
  • [5] Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (< 50 years) obese patients with type 2 diabetes mellitus
    Van Gaal, Luc
    Souhami, Elisabeth
    Zhou, Tianyue
    Aronson, Ronnie
    JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2014, 1 (02): : 31 - 37
  • [6] Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function
    Asuka Morita
    Eri Mukai
    Ayano Hiratsuka
    Tomozumi Takatani
    Toshihiko Iwanaga
    Eun Young Lee
    Takashi Miki
    Endocrine, 2016, 51 : 429 - 439
  • [7] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    Drucker, Daniel J.
    Nauck, Michael A.
    LANCET, 2006, 368 (9548): : 1696 - 1705
  • [8] Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function
    Morita, Asuka
    Mukai, Eri
    Hiratsuka, Ayano
    Takatani, Tomozumi
    Iwanaga, Toshihiko
    Lee, Eun Young
    Miki, Takashi
    ENDOCRINE, 2016, 51 (03) : 429 - 439
  • [9] Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?
    Andersen, Emilie S.
    Lund, Asger
    Bagger, Jonatan I.
    Andreasen, Camilla
    Grondahl, Magnus F.
    Deacon, Carolyn F.
    Hartmann, Bolette
    Holst, Jens J.
    Knop, Filip K.
    Vilsboll, Tina
    DIABETES OBESITY & METABOLISM, 2018, 20 (08): : 1937 - 1943
  • [10] Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists
    Wang, Yufan
    Zhao, Li
    Huang, Qianfang
    Peng, Yongde
    JOURNAL OF DIABETES, 2014, 6 (02) : 164 - 166